Incretin Atlas › Trials › TG103 phase 3 vs dulaglutide (T2D)
TG103 phase 3 vs dulaglutide (T2D)
TG103 · t2d
Design
- Molecule(s)
- TG103
- Population
- t2d
- Phase
- 3
- Duration
- 28 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TG103 15 mg vs dulaglutide: HbA1c −1.38 % | t2d china | 28 | — | — | — | −1.4 | — | — | — | — | — | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: TG103 phase 3 vs dulaglutide (T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/tg103-phase-3-vs-dulaglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.